VIDEO: CheckMate 816 trial supports treatment prior to surgery for resectable NSCLC
In this video, Sonam Puri, MD, discusses the surgical outcomes from the phase 3 CheckMate 816 trial presented at this year’s virtual annual ASCO meeting.
Additional lines of therapy can increase toxicity, causing adverse events for patients and ultimately delaying surgery. This can be a major concern for surgeons who want surgery performed as soon as possible, according to Puri, assistant professor in the division of oncology in the department of medicine at the University of Utah.
“This study really showed that the data was positive, very reassuring for the surgical outcomes that were presented,” she said.
Collapse
Healio Interview
Spicer J, et al. Abstract 8503. Presented at: ASCO Annual Meeting; June 4-8, 2021 (virtual meeting).
Read more about